Welcome to our dedicated page for Myomo news (Ticker: MYO), a resource for investors and traders seeking the latest updates and insights on Myomo stock.
Myomo, Inc. (NYSE American: MYO) is a wearable medical robotics company whose news flow centers on its MyoPro myoelectric orthosis product line, financial performance and commercialization efforts. The company develops and markets powered upper-limb orthoses designed to support the arm and restore function to weakened or paralyzed arms in patients with neurological disorders and neuromuscular injuries.
News about Myomo frequently includes quarterly financial and operating results, where the company reports revenue, gross margin, operating expenses, net loss and non-GAAP metrics such as Adjusted EBITDA. These updates also describe operating metrics such as MyoPro revenue units, orders and insurance authorizations, patient pipeline size, backlog and the proportion of revenue associated with Medicare Part B patients.
Investors following MYO can also expect announcements about product developments, such as the launch of the MyoPro 2x, which Myomo characterizes as a major step forward in donning, fit and function for users. Additional news items cover marketing and commercialization initiatives, including engagement with orthotics and prosthetics providers, training of Certified Prosthetists Orthotists, and programs like MyoConnect that are intended to generate recurring patient referrals from therapists and physicians.
Myomo’s news releases may also highlight capital markets and corporate events, including participation in investor conferences, Investor & Analyst Day presentations, and financing arrangements such as loan facilities documented in Form 8-K filings. For readers tracking MYO, this news page aggregates company-issued press releases and related updates, providing a single location to review Myomo’s reported progress on its business model, product line and financial performance over time.
Myomo, Inc. (NYSE American: MYO) has announced that Techniker Krankenkasse (TK), Germany's largest statutory health insurance, now reimburses MyoPro on a case-by-case basis. This adds to existing coverage from other major German insurers, collectively covering 28 million lives. Approximately 90% of the German population is insured under SHI. Allianz, a private insurer, also authorized MyoPro. Myomo aims to become a global standard for patients with arm paralysis, supported by a network of 35 facilities in Germany.
Myomo, Inc. (NYSE American: MYO) has announced its presentation at the Winter Wonderland – Best Ideas from the Buy-side Conference, scheduled virtually from February 16th to February 19th. Myomo will showcase its innovative solutions for those with neurological disorders and upper-limb paralysis on February 16th at 10:00 a.m. Eastern time. The presentation can be accessed through a link provided in the Investor Relations section of Myomo’s website.
Myomo specializes in wearable robotics, particularly the MyoPro product line, which enhances arm and hand functionality for affected individuals.
Myomo, Inc. (NYSE American: MYO) has signed a joint venture agreement with Beijing Ryzur Medical Investment Co., Ltd. to manufacture and sell its products in greater China, including Hong Kong, Macau, and Taiwan. Myomo will hold a 19.9% stake in the JV named Jiangxi Myomo Medical Assistive Appliance Co., Ltd., with Ryzur Medical investing $8-$20 million over five years. The JV aims to address the 14 million people suffering from chronic arm paralysis in China, leveraging Myomo's MyoPro technology.
Myomo, Inc. (NYSE American: MYO) reported preliminary financial results for Q4 and the full year 2020, forecasting revenue growth of 110% to 143% year-over-year for Q4, expected to be between $3.2 million and $3.7 million. The total revenue for 2020 is anticipated to be between $7.0 million and $7.5 million, marking an increase of 84% to 97%. Cash utilization reached a record low of approximately $1.1 million in Q4. Myomo aims for cash flow breakeven by Q4 2021, despite challenges posed by COVID-19.
Myomo, Inc. (NYSE American: MYO) announced that CEO Paul Gudonis and CFO David Henry will present at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021. The presentation will be accessible starting January 11, 2021, at 6:00 a.m. Eastern time, and will be archived for 90 days. Myomo specializes in wearable medical robotics aimed at improving functionality for patients with neurological disorders and upper-limb paralysis, mainly through its MyoPro product line, which uses EMG signals to restore upper limb function.
Myomo, Inc. (NYSE American:MYO), a company focused on wearable medical robotics, has been invited to present at the MicroCap Rodeo Best Ideas Bowl from October 13-16, 2020. Myomo's presentation is scheduled for October 13 at 4:30 p.m. ET, featuring CEO Paul Gudonis and CFO David Henry. The conference will showcase 25 top investment ideas from institutional investors, aiming to identify opportunities for alpha generation. Myomo's MyoPro product line aids those with upper-limb paralysis, enabling daily activities and promoting independence.
Myomo, Inc. (NYSE American:MYO) announced its participation in the LD 500 investor conference on September 2, 2020, at 11:00 a.m. EDT. The presentation will be led by CEO Paul Gudonis and CFO David Henry, streamed to a virtual audience. This marks a significant opportunity for Myomo to showcase its advancements in wearable medical robotics that aid those with neurological disorders. The LD 500 conference runs from September 1-4, and interested parties can register for the real-time presentation online, with a replay available on Myomo's website.